Abstract: The bicyclic derivatives of pyridines of the formula ##STR1## and their non-toxic, pharmaceutically acceptable salts and a process and intermediates for their preparation which compounds are inhibitors of angiotensin II effects, particularly a vasoconstrictor activity.

Abstract: Products of formula (I): ##STR1## in which: R.sub.1, R.sub.2, R.sub.3 and R.sub.4 represent:--a hydrogen atom, a halogen atom, one of the following radicals: hydroxyl, mercapto, cyano, nitro, sulpho, formyl, benzoyl, acyl, carboxy, cycloalkyl, acyloxy,--an alkyl, alkenyl, alkynyl, alkyloxy or alkythio radical,--an alkyl, alkenyl, alkynyl, alkyloxy or alkylthio radical,--an aryl, arylalkyl, arylalkenyl, aryloxy or arylthio radical,--a radical: ##STR2## --a--(CH.sub.2).sub.m1 --S(O).sub.m2 --Z'--R'.sub.14 radical in which m1 represents an integer from 0 to 4, m2 represents an integer from 0 to 2, R.sub.5 represents a divalent alkylene radical, Y represents the --Y.sub.1 --B--Y.sub.2 radical.These products have useful pharmacological properties, which justify their use as medicaments.

Abstract: The bicyclic derivatives of pyridines of the formula ##STR1## and their non-toxic, pharmaceutically acceptable salts and a process and intermediates for their preparation which compounds are inhibitors of angiotensin II effects, particularly a vasoconstrictor activity.

Abstract: Novel bicyclic compounds in all possible racemic, enantiomeric and diasteroisomeric forms of the formula ##STR1## having antagonistic properties for angiotensin II receptors and novel intermediates and process for their preparation.

Abstract: A compound in all racemic or optionally active forms selected from the group consisting of a compound of the formula ##STR1## where the substituents are defined as in the specification and their non-toxic, pharmaceutically acceptable acid addition salts having anti-anoxic activity and a novel process and intermediates for their preparation.

Abstract: The bicyclic derivatives of pyridines of the formula ##STR1## and their non-toxic, pharmaceutically acceptable salts and a process and intermediates for their preparation which compounds are inhibitors of angiotensin II effects, particularly a vasoconstrictor activity.

Abstract: Novel bicyclic compounds in all possible racemic, enantiomeric and diasteroisomeric forms of the formula ##STR1## having antagonistic properties for angiotensin II receptors and novel intermediates and process for their preparation.

Abstract: A compound selected from the group consisting of a compound of the formula ##STR1## wherein R.sub.1 and R.sub.2 are individually selected from the group consisting of hydrogen, halogen, alkyl and alkoxy of 1 to 5 carbon atoms, hydroxy, trifluoromethyl and nitro, n is 0,1 or 2 and the group: ##STR2## in all possible racemic or optically active isomer forms and their non-toxic, pharmaceutically acceptable acid addition salts having analgesic, anti-anoxic and anti-ischemic neuronal protective properties.